Alexion price target raised to $205 from $125 at Deutsche Bank Deutsche Bank raised its price target for shares of Alexion Pharmaceuticals to $205 citing upside potential from the company's launch of Asfotase Alfa for severe Hypophosphatasia. The firm keeps a Buy rating on the stock.
News For ALXN From The Last 14 Days
Check below for free stories on ALXN the last two weeks.
Alexion price target raised to $199 from $175 at RW Baird Baird raised its price target on Alexion following successful negotiations with the French government regarding reimbursement rates for aHUS. The company raised its guidance and the firm raised its earnings estimates and Soliris estimates and calls Alexion a core large-cap holding. Shares are Outperform rated.